Does Rallies show 13F holders for ALKS?

Yes. Rallies tracks hedge fund and 13F ownership data for ALKS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ALKS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALKS. It does not provide personalized investment advice.

ALKS (Alkermes Inc. plc) Stock Analysis - Hedge Fund Holdings

Alkermes Inc. plc (ALKS) is a publicly traded Healthcare sector company. As of May 21, 2026, ALKS trades at $36.98 with a market cap of $6.20B and a P/E ratio of 40.06. ALKS moved -0.08% today. Year to date, ALKS is +32.07%; over the trailing twelve months it is +16.77%. Its 52-week range spans $25.17 to $39.56. Analyst consensus is strong buy with an average price target of $45.75. Rallies surfaces ALKS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ALKS stock?

Hedge funds tracked by Rallies that own ALKS include Panagora Asset, Bridgewater Associates, Centerbook Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Alkermes Inc. plc.

ALKS Key Metrics

Key financial metrics for ALKS
Metric	Value
Price	$36.98
Market Cap	$6.20B
P/E Ratio	40.06
EPS	$0.93
Dividend Yield	0.00%
52-Week High	$39.56
52-Week Low	$25.17
Volume	0
Avg Volume	0
Revenue (TTM)	$1.56B
Net Income	$152.72M
Gross Margin	86.63%

Top Hedge Funds Holding ALKS

Panagora Asset holds 932.94K shares of ALKS, changed +0.43% as of Mar 31, 2026.
Bridgewater Associates holds 83.81K shares of ALKS, changed -75.67% as of Mar 31, 2026.
Centerbook Partners holds 38.63K shares of ALKS, changed +38.30% as of Mar 31, 2026.
Farallon Capital holds 20.80K shares of ALKS, changed +0.00% as of Mar 31, 2026.

Latest ALKS News

Alkermes jumps after positive Phase 3 REVITALYZ topline results for LUMRYZ in IH — May 12, 2026
Alkermes falls as investors digest Q1 GAAP loss and Avadel accounting impacts — May 6, 2026
Alkermes Price Target Raised to $50 After Q1 Revenue Beat and $80.3M EBITDA — May 6, 2026
Alkermes climbs after Q1 revenue beat and Avadel-driven 2026 outlook update — May 5, 2026
Alkermes climbs as traders position ahead of May 5 Q1 results, orexin pipeline focus — May 4, 2026

Recent ALKS Insider Trades

Gaffin David Joseph sold 2.03K (~$67.53K) on May 4, 2026.
Hopkinson Craig C. sold 9.00K (~$300.56K) on May 1, 2026.
Gaffin David Joseph sold 2.03K (~$70.32K) on Apr 6, 2026.

ALKS Analyst Consensus

15 analysts cover ALKS: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.75.

Common questions about ALKS

Who owns ALKS stock?: Hedge funds tracked by Rallies that own ALKS include Panagora Asset, Bridgewater Associates, Centerbook Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Alkermes Inc. plc.
Does Rallies show 13F holders for ALKS?: Yes. Rallies tracks hedge fund and 13F ownership data for ALKS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ALKS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALKS. It does not provide personalized investment advice.